Salipro Biotech Awarded European Patent for Direct Extraction of Membrane Proteins and Library Generation
Salipro® platform technology strengthened to accelerate discovery programs for therapeutic antibodies and small molecule drugs against challenging drug targets
Stockholm, Sweden, February 17, 2021 –Swedish biotech company Salipro Biotech AB today announced that the European Patent Office has issued the European Patent No. 3463303, titled “Saposin lipoprotein particles and libraries from crude membranes”. The patent covers the company’s novel method of direct extraction of membrane proteins (DirectMX™) from cells or crude membranes to enable drug development for challenging drug targets, as well as for the generation of libraries with Salipro® particles representing the membrane proteome, the particles themselves and their uses.
The key application is in drug discovery where membrane proteins represent the targets of more than 60% of drugs in clinical use. However, progress in drug development is often hampered by the inherent instability of membrane proteins – a major problem which is addressed by the Salipro platform technology to stabilize those important drug targets.
Jens Frauenfeld, CEO, comments: “Ever since its inception, DirectMX™ has had a profound impact on how we accelerate drug discovery with our pharma partners. Our foundational IP covering the Salipro® platform technology has already resulted in various patents being granted to Salipro Biotech in the US, EU, China and Japan, and this patent will provide additional broad protection for our proprietary platform technology for the stabilization of challenging drug targets.”
Maria Knudsen, Business Developer, comments: “DirectMX™ is rapidly becoming established as a key drug discovery platform and we are already partnering with major pharma companies on a range of targets, including GPRCs, SLCs and Ion Channels. Further strengthening our patent portfolio will enable us to increase the value of such collaborations as well as moving towards building our own discovery pipeline.”
About Salipro Biotech AB
Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.
The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design.
To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs.
Press contact:
Salipro Biotech AB
Maria Lisa Knudsen
Business Developer
+46 (0)72 939 5018
maria.knudsen@salipro.com
https://www.salipro.com
